The effect of different dosages of Methylprednisolone on platelet function and fibrinolysis system in cardiopulmonary bypass patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201010233438N2

Enrollment

Registered

2010-12-03

Start date

2010-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Ischeamic heart diseases. Condition 2: Coagulation defects. Atherosclerotic heart disease Coagulation defects, unspecified

Interventions

Intervention 1: Drug intervention: Methylprednisolone Interavenous, one time, before anesthesia, dose 5mg/kg. Intervention 2: Drug intervention: Methylprednisolone Interavenous, one time, before ane

Treatment - Drugs

Drug intervention: Methylprednisolone Interavenous, one time, before anesthesia, dose 5mg/kg

Drug intervention: Methylprednisolone Interavenous, one time, before anesthesia, 15mg/kg

Eligibility

Sex/Gender

All

Age

50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1- Patients with coronary artery disease undergoing elective surgery 2- Both male and female patients are eligible 3- between 50 and 70 years old 4- Not having a aspirin 5 days prior to surgery 5- Not using heparin and any other steroid

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Blood loss. Timepoint: 24 hour after operation. Method of measurement: Scaled buttel tube.;Blood product requirements. Timepoint: At operation and ICU room. Method of measurement: The number of bags.	—

Secondary

Measure	Time frame
D-dimer. Timepoint: Pre-operation, after heparin neutralization. Method of measurement: Instrument.;CK - MB enzyme. Timepoint: Pre-operation, 6, 12 hours after operation. Method of measurement: Instrument.;Platelet count. Timepoint: Pre-operation, 6, 12 hours after operation. Method of measurement: Instrument.;HCT. Timepoint: Pre-operation, 6, 12 hours after operation. Method of measurement: Instrument.;Prothrombin Time. Timepoint: Pre-operation, 6, 12 hours after operation. Method of measurement: Instrument.;Partial Thromboplastin Time. Timepoint: Pre-operation, 6, 12 houra after operation. Method of measurement: Instrument.;The expression of platelet receptors. Timepoint: Pre-operation, after heparin neutralization. Method of measurement: Flowcytometry.;Tissue Plasminogen Activator. Timepoint: Pre-operation, after heparin neutralization. Method of measurement: ELISA.;Platelet response to agonists. Timepoint: Pre-operation, after heparin neutralization. Method of measurement: Aggregometry.;Plasminogen Activator Inhibitor. Timepoint: Pre-operation, after heparin neutralization. Method of measurement: ELISA.	—

Measure

Time frame

D-dimer. Timepoint: Pre-operation, after heparin neutralization. Method of measurement: Instrument.;CK - MB enzyme. Timepoint: Pre-operation, 6, 12 hours after operation. Method of measurement: Instrument.;Platelet count. Timepoint: Pre-operation, 6, 12 hours after operation. Method of measurement: Instrument.;HCT. Timepoint: Pre-operation, 6, 12 hours after operation. Method of measurement: Instrument.;Prothrombin Time. Timepoint: Pre-operation, 6, 12 hours after operation. Method of measurement: Instrument.;Partial Thromboplastin Time. Timepoint: Pre-operation, 6, 12 houra after operation. Method of measurement: Instrument.;The expression of platelet receptors. Timepoint: Pre-operation, after heparin neutralization. Method of measurement: Flowcytometry.;Tissue Plasminogen Activator. Timepoint: Pre-operation, after heparin neutralization. Method of measurement: ELISA.;Platelet response to agonists. Timepoint: Pre-operation, after heparin neutralization. Method of measurement: Aggregometry.;Plasminogen Activator Inhibitor. Timepoint: Pre-operation, after heparin neutralization. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mahnoosh Foroughi

Clinical research of Modarres Hospital

m_foroughi@sbmu.ac.ir+98 917 161 3954

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026